Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: cameron c. Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23. Curr Med Res Opin. 2021. PMID: 34256668 Clinical Trial.
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.
Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A. Kumar S, et al. Among authors: cameron c. Leuk Lymphoma. 2019 Jan;60(1):163-171. doi: 10.1080/10428194.2018.1459609. Epub 2018 May 9. Leuk Lymphoma. 2019. PMID: 29741423
Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Salvo EM, Samjoo IA, Tran D, Cameron C. Salvo EM, et al. Among authors: cameron c. Expert Opin Pharmacother. 2019 Aug;20(12):1527-1528. doi: 10.1080/14656566.2019.1620983. Epub 2019 May 24. Expert Opin Pharmacother. 2019. PMID: 31124724 No abstract available.
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Dahlke F, Adlard N. Samjoo IA, et al. Among authors: cameron c. Curr Med Res Opin. 2020 Jul;36(7):1145-1156. doi: 10.1080/03007995.2020.1747998. Epub 2020 Apr 14. Curr Med Res Opin. 2020. PMID: 32216597
Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. Among authors: cameron c. J Comp Eff Res. 2021 Apr;10(6):495-507. doi: 10.2217/cer-2020-0267. Epub 2021 Feb 23. J Comp Eff Res. 2021. PMID: 33620251 Free article.
1,477 results